Indusatumab vedotin is an antibody-drug conjugate (ADC) consisting of an antibody targeting human guanylate cyclase C (GCC) conjugated with the microtubule inhibitor monomethyl auristatin. It can inhibit the proliferation of pancreatic cancer cells, arrest the cell cycle at G2/M phase, and induce apoptosis.

Indusatumab vedotin exerts significant anti-proliferative effects on pancreatic cancer cell lines when treated at 0.4–25 μg/mL for 72 h.Treatment of MIA PaCa-2 and PANC-1 cells with 12.5 μg/mL for 24 h induces cell cycle arrest at G2/M phase and promotes the expression of phosphorylated histone H3 (P-Histone H3) [1].

Indusatumab vedotin administered intravenously at 10 mg/kg once weekly for at least 17 consecutive days significantly inhibits tumor growth rate [1].Indusatumab vedotin demonstrates biological effects highly correlated with drug exposure in mice bearing one of six xenograft tumor models [2].

Human

Monoclonal, ADC

MMAE